Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
SAN DIEGO, April 24, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company, today announced that the company will host a conference call and live webcast on Tuesday, May 7, 2024, at 8:30 a.m. ET to report first quarter 2024 financial results and discuss recent business highlights.
聖地亞哥，2024年4月24日 /PRNewswire/ — 處於商業階段的生物技術公司Heron Therapeutics, Inc.（納斯達克股票代碼：HRTX）今天宣佈，該公司將於美國東部時間2024年5月7日星期二上午8點30分舉行電話會議和網絡直播，公佈2024年第一季度財務業績並討論最近的業務亮點。
The conference call can be accessed by dialing (646) 307-1963 in the U.S. or (800) 715-9871 internationally. Please provide the operator with the passcode 1497932 to join the conference call. The conference call will also be available via webcast under the Investor Relations section of Heron's website at . An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.
可以在美國撥打 (646) 307-1963 或撥打 (800) 715-9871 進行電話會議。請向接線員提供密碼 1497932 以加入電話會議。電話會議還將通過Heron網站的 “投資者關係” 部分下的網絡直播播出，網址爲。電話會議和網絡直播的檔案也將在電話會議結束後的60天內在Heron的網站上公佈。
About Heron Therapeutics, Inc.
關於 Heron Therapeutics, Inc.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit .
Heron Therapeutics, Inc. 是一家處於商業階段的生物技術公司，專注於通過開發和商業化改善醫療保健的治療創新來改善患者的生活。我們先進的科學、專利技術和創新的藥物發現和開發方法使我們能夠創建和商業化一系列旨在提高急性護理和腫瘤患者的護理標準的產品組合。欲了解更多信息，請訪問。
Forward-looking Statements
前瞻性陳述
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
本新聞稿包含1995年《私人證券訴訟改革法》所定義的 “前瞻性陳述”。Heron提醒讀者，前瞻性陳述基於管理層截至本新聞稿發佈之日的預期和假設，存在某些風險和不確定性，可能導致實際業績存在重大差異。這些風險和不確定性包括但不限於公司向美國證券交易委員會提交的文件中確定的風險和不確定性。前瞻性陳述僅在規定的日期反映我們的分析，除非法律要求，否則Heron沒有義務更新或修改這些陳述。
Investor Relations and Media Contact:
投資者關係和媒體聯繫人：
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
[email protected]
858-251-4400
艾拉·杜阿爾特
執行副總裁、首席財務官
Heron Therapeutics, Inc
[電子郵件保護]
858-251-4400
SOURCE Heron Therapeutics, Inc.
來源 Heron Therapeutics, Inc.
譯文內容由第三人軟體翻譯。